Maintaining Our $107 BioMarin FVE Following 2017 Results
We’re maintaining our $107 fair value estimate for BioMarin following 2017 earnings and a 2018 management forecast that were in line with our expectations. In the long run, the firm is still guiding to a top-line growth rate around 15% through 2020 and expenses shrinking as a percentage of sales, with products like achondroplasia drug vosoritide and hemophilia A gene therapy val-rox driving stronger growth beyond 2020. Our model projects midteens growth in 2018 and 2019, with an increase in grow...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.